Product Information
POTASSIUM CL 20 MEQ PACKET is a generic product labeled by Virtus Pharmaceuticals, LLC, priced at $0.5943 per EA under NDC 69543045110. Its NADAC has been published 286 times since Mar 17, 2021.
FDA first approved this application on Nov 23, 2018. Its Orange Book therapeutic-equivalence code is AA.
The High Outlier badge above means this manufacturer's average price in the Potassium Chloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1.5 g/1.77g
Manufacturer
Virtus Pharmaceuticals, LLCNDC
69543045110
Classification
Generic
Dosage Form
POWDER, FOR SOLUTION
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
POTASSIUM CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210200FDA Approved
11/23/2018
TE Code
AA
On Market Since
1/1/2021
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CL 20 MEQ PACKET has been published 286 times since Mar 17, 2021, and over the history we have for it it has declined 77.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5943 per EA |
|---|---|
| All-time high | $2.8729 (Jul 12, 2023) |
| All-time low | $0.5943 (Aug 19, 2026) |
| 52-week high | $0.9641 |
| 52-week low | $0.5943 |
| Median price | $1.6689 |
| Average price | $1.6126 |
| Largest weekly change | -47.9% (Jul 19, 2023) |
| Weeks tracked | 286 |
| Tracking since | Mar 17, 2021 |
1W
N/A
1M
N/A
3M
-5.8%
6M
-4.5%
1Y
-38.4%
3Y
-41.4%
5Y
-73.8%
All
-77.6%
Last surveyed Sep 2, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Virtus Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Potassium Chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CL 20 MEQ PACKET?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CL 20 MEQ PACKET, manufactured by Virtus Pharmaceuticals, LLC, is $0.5943 per EA (NDC 69543045110), effective Sep 2, 2026.
How has the price of POTASSIUM CL 20 MEQ PACKET changed over time?
Over the history we have for it, the NADAC for POTASSIUM CL 20 MEQ PACKET has declined 77.6%. It has been tracked across 286 weekly CMS publications since Mar 17, 2021.
What are the highest and lowest recorded NADAC prices for POTASSIUM CL 20 MEQ PACKET?
Since Mar 17, 2021, the NADAC for POTASSIUM CL 20 MEQ PACKET has ranged from a low of $0.5943 (Aug 19, 2026) to a high of $2.8729 (Jul 12, 2023), with a median of $1.6689 per EA.
Are there cheaper alternatives to POTASSIUM CL 20 MEQ PACKET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as POTASSIUM CL 20 MEQ PACKET in a comparable dosage form, but none are currently priced below it.
Who manufactures POTASSIUM CL 20 MEQ PACKET?
POTASSIUM CL 20 MEQ PACKET (NDC 69543045110) is labeled by Virtus Pharmaceuticals, LLC, and CMS classifies it as a generic product.